Why Co-Diagnostics Zoomed Almost 10% Higher Today

Co-Diagnostics (NASDAQ: CODX) was an investor-pleasing machine at the tail end of the week. After reporting highly encouraging Q2 earnings after market close on Thursday, the company's stock unsurprisingly leapt by just under 10% the following day.

Co-Diagnostics beat every collective analyst estimate for its most important metrics during the quarter. The company, which has risen to prominence even among non-healthcare investors because of its COVID-19 diagnostic products, said that its revenue was $27.4 million. That was nearly 14% higher on a year-over-year basis, and easily topped the average prognosticator forecast of almost $20.8 million.

Image source: Getty Images.

Source Fool.com